Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients

N Ady1,6, L Morat1,6, K Fizazi2, J-C Soria1,2, M-C Mathieu3, D Prapotnich4, L Sabatier*,1 and L Chauveinc1,5

1CEA, Laboratoire de Radiobiologie et Oncologie, DRR/DYS, 92265 Fontenay-aux-Roses, France; 2Département de Médecine, Institut Gustave Roussy, 94805 Villejuif, France; 3Département d’Anatomopathologie, Institut Gustave Roussy, 94805 Villejuif, France; 4Service d’Urologie, Institut Mutualiste Montsouris, 75014 Paris, France; 5Département de Radiothérapie, Institut Cane, 75005 Paris, France

HER-2/neu may play a role in prostate carcinogenesis. The aim of this study was to use the expression of HER-2/neu as a molecular marker for the detection of circulating tumour cells (CTCs) in the blood of patients with prostate cancer (PC). Blood samples were collected from 42 patients with PC and nine healthy volunteers. Immunomagnetic beads were used to harvest epithelial cells from peripheral blood mononuclear cells. Total RNA was extracted and reverse transcribed before analysis by real-time PCR with HER-2/neu-specific primers. CTCs were HER-2/neu positive in six out of 11 (54%) patients with metastatic disease and in three out of 31 (9.6%) patients with localised PC (P = 0.004). In blood samples from nine healthy volunteers, we detected no expression of HER-2/neu. The present method appears to be minimally invasive, highly sensitive and a specific approach for detecting CTCs in PC. Furthermore, it may help better target HER-2/neu in advanced PC.

Keywords: HER-2/neu; circulating tumour cells; prostate cancer; metastatic process

Prostate cancer (PC), the most common cancer in men in western countries, presents a dynamic process in which different clinical and biological phases in both the natural and treated history of the disease may be characterised (Scher and Heller, 2000). The pathways that underlie tumour progression, invasion and resistance to treatment in each clinical state are being increasingly understood, and novel biologic targets that relate these pathways are in development or are now available for clinical testing. On the other hand, establishment of new biomarkers is needed to identify high-risk patients as candidates for new (adjuvant) therapies and to find new surrogate endpoints to assess the efficacy of these treatments (De Marzo et al., 2001).

Among serum markers of prostate carcinogenesis, the detection of circulating tumour cells (CTCs) by RT-PCR for prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) mRNA proved to be positive in both peripheral blood and bone marrow (BM). The level of CTCs detected in this setting ranges from 0 to 72% in patients with clinically organ confined (T1-2) disease and from 25 to 100% in patients with distant metastases (Ishaula et al., 1994; Katz et al., 1994; Ghossein et al., 1995; Seiden et al., 1995; Sokoloff et al., 1996; Corey et al., 1997; Wood and Banerjee, 1997; Mejean et al., 2000; Hara et al., 2002). However, the major question of the specificity of the RT-PCR approach remains unanswered because of illegitimate transcripts in lymphocytes or other blood cells.

The detection of CTCs using more specific markers such as overexpression of HER-2/neu may be more attractive. The HER-2/neu oncogene is located on chromosome 17q21 and it encodes a 185 kDa transmembrane tyrosine kinase receptor of the epidermal growth factor receptor family (Schechter et al., 1985; Yamamoto et al., 1986). Amplification of the HER-2/neu gene and/or overexpression of the protein are found in a variety of human cancers and a number of clinical studies have attempted to correlate its presence with poor patient prognosis (Hynes, 1993; Hynes and Stern, 1994). In breast cancer, HER-2/neu amplification or overexpression, according to standardised criteria, has been described as a marker predicting both response to treatment and poor prognosis with nodal metastases (Slamon et al., 1987; Menard et al., 2000; Yamauchi et al., 2001). Targeting HER-2 using a humanised monoclonal antibody (trastuzumab, Herceptine®) in combination with chemotherapy confers a survival benefit for patients with metastatic breast carcinoma that overexpress HER-2 (Slamon et al., 2001), raising the possibility of therapeutic benefits for other types of malignancies that similarly express HER-2. Although the assessment of HER-2/neu overexpression in PC varies widely due to procedural differences, evidence suggests that HER-2/neu may be important in cancer progression (Signoretti et al., 2000). Antitumour activity of anti-HER-2/neu antibody was shown in both androgen-dependent and -independent human xenograft models (Agus et al., 1999). Preliminary clinical trials of trastuzumab have been performed in metastatic PC (Small et al., 2001; Morris et al., 2002). The results of these trials underscored the requirement to better access HER-2/neu expression in order to identify subgroups of patients who may benefit from HER-2/neu targeting.
The aim of the present study was to use the expression of HER-2/neu as a molecular marker for the detection of cancer cells in the blood of 42 patients with PC and various clinical stages. Indeed, compared to other molecular markers (e.g., PSA), HER-2/neu has several advantages: it plays a role in prostate tumour progression, and it represents a potential therapeutic target since a commercially available antibody exists and has been successfully tested in the setting of breast cancer. In addition, overexpression of HER-2/neu is highly specific for cancer cells and has never been reported in the blood cells. Therefore, the use of HER-2/neu avoids the problem related to illegitimate transcripts in lymphocytes or other blood cells.

MATERIALS AND METHODS

Patients

A total of 42 men, aged 54–81 years, with histologically confirmed PC were included in this study. Blood samples were collected before any treatment in patients with localised PC and during hormone therapy in patients with metastases. All the blood samples were taken at an interval from any biopsy or digital examination for patients who underwent surgery, blood was collected the day before the surgical procedure. According to clinical status and treatment, patients were divided into two groups: 11 patients with distant metastasis receiving hormone therapy (group 1) and 31 patients with localised PC (group 2). Among patients with localised PC (n = 31), 18 were treated by radical prostatectomy (patient nos. 12–29) and 13 by radiation therapy, PC was clinically and radiologically defined. All these patients underwent endorectal coil MRI, in order to rule out extracapsular or seminal vesicules invasion. Nine healthy male volunteers, aged 34–60 years, were selected as a negative control group.

Blood samples and immunomagnetic separation of circulating epithelial cells

Blood samples (20 ml) were collected in heparinised tubes and stored at 4°C for a maximum of 2 h before the experiments. Epithelial cells were separated as described by Soria et al., 1999.

Table 1 Clinical, pathological and biological status of 11 patients with metastatic prostate carcinoma* (group 1)

| Patient no. | Age | Score of gleason | Plasmatic marker: PSA** | Treatment | Circulating tumour cells Status HER-2/neu: RT-PCR (LightCycler) |
|------------|-----|------------------|-------------------------|-----------|---------------------------------|
| 1          | 79  | 2                | + 15                    | HT        | –                               |
| 2          | 67  | 7                | + 0.8                   | HT        | +                               |
| 3          | 67  | 7                | + 88                    | HT        | +                               |
| 4          | 79  | 7                | + 0.9                   | HT        | –                               |
| 5          | 74  | 7                | + 2.28                  | None      | +                               |
| 6          | 74  | 4                | + 0.1                   | HT        | –                               |
| 7          | 81  | 4                | + 2.9                   | HT        | +                               |
| 8          | 72  | 7                | + 3.1                   | HT        | –                               |
| 9          | 68  | 7                | + 82.3                  | HT        | –                               |
| 10         | 78  | 5                | + 508                   | HT        | +                               |
| 11         | 80  | 4                | + 492                   | HT        | +                               |

*HT = hormonotherapy; CTC = circulating tumour cell; PSA = prostate-specific antigen. **Normal value for PSA: <5 ng ml⁻¹.

Hypaque and resuspended in 1 ml of PBS-2% FCS. Then, 12.5 × 10⁶ prewashed immunomagnetic beads covalently coated with the BerEP4 monoclonal antibody (Dynal A.S., Oslo, Norway) were added. BerEP4 monoclonal antibody recognises an epitope on the protein moiety of 2 glycopeptides (34 and 39 kDa) expressed at the surface of epithelial cells in normal and malignant tissues (Latza et al., 1990). Following incubation at 4°C for 30 min, cells bound to the beads were harvested using a magnetic field. The harvested epithelial cells (HECs) were then washed six times with PBS–2% FCS. Washing efficiency was controlled by microscopic examination to verify that the samples only contained immunomagnetic bead-coated cells. Cells and beads were then stored at −80°C in two Eppendorf tubes for PCRs.

RNA extraction

RNA was extracted from cells using the commercially available kit (RNeasy 74104, Qiagen, Hilden, Germany). Samples were stored at −80°C for up to 4 weeks before the assay.

cDNA synthesis

The detection of HER-2/neu mRNA was performed in a two-step procedure as described by the LightCycler HER-2/neu RNA detection kit (Roche Diagnostics, Germany).

Table 2 Clinical, pathological and biological status of 31 patients with localised prostate carcinoma* before radical prostatectomy (patients 12–29) and before treatment by radiation therapy (patients 30–42)

| Patient no. | Age | Score of gleason | Plasmatic marker: PSA** | Treatment | Circulating tumour cells Status HER-2/neu: RT-PCR (LightCycler) |
|------------|-----|------------------|-------------------------|-----------|---------------------------------|
| 12         | 62  | 6                | 2b X 0                  | 16.3      | –                               |
| 13         | 74  | 7                | 3b I 0                  | 17.9      | –                               |
| 14         | 68  | 5                | 2a X 0                  | 8         | –                               |
| 15         | 66  | 5                | 3a X 0                  | 8.8       | –                               |
| 16         | 79  | 6                | 3a X 0                  | 12.2      | –                               |
| 17         | 64  | 7                | 2a X 0                  | 9.1       | –                               |
| 18         | 67  | 5                | 2b X 0                  | 5.9       | –                               |
| 19         | 69  | 6                | 2b X 0                  | 13.3      | –                               |
| 20         | 62  | 7                | 3b X 0                  | 12.5      | –                               |
| 21         | 60  | 6                | 2b X 0                  | 7.1       | –                               |
| 22         | 76  | 6                | 2b X 0                  | 11        | –                               |
| 23         | 72  | 6                | 2a X 0                  | 7         | –                               |
| 24         | 62  | 6                | 2b X 0                  | 0.9       | –                               |
| 25         | 66  | 9                | 3b X 0                  | 8.5       | –                               |
| 26         | 57  | 7                | 3b X 0                  | 8.2       | –                               |
| 27         | 78  | 9                | 3b X 0                  | 6.3       | –                               |
| 28         | 65  | 5                | 2b X 0                  | 2.6       | –                               |
| 29         | 55  | 6                | 2b X 0                  | 33        | –                               |
| 30         | 78  | 2                | 1c 0                   | 6.4       | –                               |
| 31         | 67  | 7                | 1c 0                   | 6.1       | –                               |
| 32         | 74  | 5                | 1c 0                   | 10        | –                               |
| 33         | 74  | 5                | 2a 0                   | 7         | –                               |
| 34         | 63  | 6                | 2a 0                   | 35        | +                               |
| 35         | 58  | 3                | 2a 0                   | 10        | –                               |
| 36         | 75  | 7                | 2a 0                   | 9         | –                               |
| 37         | 74  | 7                | 1c 0                   | 13        | +                               |
| 38         | 54  | 6                | 1c 0                   | 10.6      | –                               |
| 39         | 58  | 6                | 1c 0                   | 5.9       | +                               |
| 40         | 57  | 8                | 2a 0                   | 20        | –                               |
| 41         | 61  | 8                | 2a 0                   | 8.9       | –                               |
| 42         | 66  | 5                | 1c 0                   | 5         | –                               |

*HT = hormonotherapy; ND = not determined; PSA = prostate-specific antigen. **Normal value for PSA: <5 ng ml⁻¹. T = pT for patients 12–29, T = clinical and radiological results for patients 30–42; N = pN for patients 12–29, N = clinical and radiological results for patients 30–42; M = radiological results.
Quantification Kit (Roche). Briefly, in the first step, cDNA was prepared from RNA by reverse transcription in a final volume of 20 μl in a thermal cycler (PTC-200, MJ Research). The samples were incubated at 25°C for 10 min, and then 42°C for 60 min and 94°C for 5 min. cDNA were stored at −20°C.

**PCR conditions**

In the second step, a 395 bp fragment of HER-2/neu mRNA was amplified from cDNA by PCR using specific primers (LightCycler-HER2/neu RNA Quantification Kit, Roche, Mannheim, Germany). The amplicon was detected by fluorescence using a specific pair of Hybridisation Probes consisting of two different oligonucleotides labelled at the 5’-end with LightCycler-Red 640 and at the 3’-end with LightCycler-Fluorescein. Only after hybridisation to the template DNA do the two probes come in close proximity, resulting in fluorescence resonance energy transfer (FRET) between the two fluorophores measured by the LightCycler instrument. The kit included a calibrator containing a stabilised fraction of total RNA purified from an immortalised cell line constitutively expressing HER-2/neu. The efficiency of PCR was assessed with serial dilutions of this calibrator in each run. For quantification, crossing point (Cp) was used, the cycle at which PCR amplification begins its exponential phase and is considered the point most reliably proportional to initial concentration. The amount of mRNA encoding for HER-2/neu is expressed as a relative ratio to a reference gene (G6PDH) in a sample relative to the Her-2/neu: G6PDH ratio in a calibrator.

Of the total reverse transcription volume of 20 μl, 4 μl was used for each PCR. The polymerase amplification was performed in a total volume of 10 μl. Each experiment was performed in duplicate. The thermal cycling conditions were: denaturation for 20 min at 95°C followed by amplification 10 s at 95°C, then 15 s at 65°C and 15 s at 72°C for 50 cycles, terminated by a cooling step 30 s at 40°C.

**RESULTS**

**Determination of assay sensitivity**

We analysed the sensitivity of the present method by serial dilutions of SK-BR-3 cell line, which is used as a reference for overexpression of HER-2/neu (Pergram et al, 1997). The lower limit of detection was that of ≤1 cell ml⁻¹ of blood (Figure 1).

**Detection of HER-2/neu transcripts in CTCs in the blood of healthy volunteers**

In blood samples from nine healthy volunteers, we detected no expression of HER-2/neu.

**Detection of HER-2/neu transcripts in CTCs in the blood of patients with PC**

**Group 1 (metastatic PC)** Group 1 included 11 patients with metastatic PC. The median age of these patients was 74 years (range, 67–81). Of these 11 patients, six (54%) were positive for the detection of HER-2/neu.

**Group 2 (localised PC)** Group 2 included 31 patients with T1c–T3b PC from whom blood was collected before treatment by radical prostatectomy or radiation therapy. The median age was 66.5 years (range, 54–79). Of these 31 patients, three (9.6%) were positive for the detection of HER-2/neu.

Tables 1 and 2 summarise the biological, clinical and pathological status of patients at sampling time.

The specific association of HER-2/neu transcripts with the presence of epithelial cells in patients with PC was demonstrated by the absence of contaminating lymphocytes in HEC samples. The washing efficiency and lack of lymphocytic contamination were controlled for each sample by microscopic examination to verify that samples only contained immunomagnetic bead-coated cells (Figure 2 shows an example of this cytologic analysis from patient #34).

We studied the relationship of HER-2/neu positivity in CTCs of patients with different clinical status. The rate of HER-2/neu detection in CTCs of patients with metastatic PC was significantly higher than that of patients with localised disease (Fisher’s exact test, P = 0.004) (see Table 3).

**Figure 1** Expression of HER-2/neu RNA by real-time PCR (LightCycler). Amplification curve shows serial dilutions of an initial amount of SK-BR-3 RNA: 1 (3333 cells), 2 (333 cells), 3 (166 cells), 4 (33 cells), 5 (16 cells), 6 (1.6 cells) and 7 (0.6 cells). Inset, standard curve plot of the log of SK-BR-3 RNA cells numbers vs Cp. The standard curve shows seven orders of linear dynamic range (y = −3.67x + 33.071; R² = 0.9983).
Table 3 HER-2/neu expression in CTCs of prostate cancer patients according to clinical status

| Patient characteristics | Number of patients | Positive cases % |
|-------------------------|--------------------|------------------|
| Metastatic PC (group 1) | 11                 | 6 (54%)          |
| Localised PC (group 2)  | 31                 | 3 (9.6%)*        |

*P = 0.004 by Fisher exact test. CTC = circulating tumour cell; PC = prostate cancer.

DISCUSSION

RT-PCR of several prostate-related genes (PSA, PSMA) as well as immunohistochemical assays (PSA, CK 18) have been used to detect circulating PC cells, but none of these techniques is currently applied in the clinical setting. To our knowledge, HER-2/neu has not been used for detecting CTCs from PC. In the present study, we have combined immunomagnetic separation of circulating epithelial cells with RT-PCR detection of the HER-2/neu transcripts, in order to increase the specificity and better characterise the molecular profile of CTCs. Nevertheless, the complexity of the present technique should be kept in mind, if its implementation in clinical practice is envisioned. Furthermore, it is important to highlight that the present procedure cannot ensure that the circulating cancer cells detected are PC cells. Indeed, such CTC could be from another epithelial cancer expressing Her2/neu (e.g. bladder cancer). Nevertheless, this is not a frequent clinical situation, especially in patients with radiological and clinical follow-ups.

Evidence suggests that co-operative signalling via c-erbB receptors (such as, HER-1, HER-2/neu, HER-3 and HER-4) can regulate many key processes such as angiogenesis and invasion in most cancers (Eccles, 2001; O-charoenrat et al, 2002). In vitro, HER-2/neu induced metastatic capacities, when it was transfected into a PC cell line (Zhu et al, 1999). When evaluated by immunohistochemistry (IHC), HER-2/neu expression varies largely from one study to another because of methodologic differences and heterogeneity of PC (Gu et al, 1996; Lara et al, 2002). The published incidence of HER-2/neu overexpression is typically in the range of 25–40% and 60–80%, respectively, in localised PC (Sadasivan et al, 1993; Ross et al, 1997; Fossa et al, 2002) and in metastatic PC (Osman et al, 2001; Morris et al, 2002). An elevation of serum HER-2/neu was also observed for detection of the extracellular domain of the protein by immunoradiometric assay in patients with advanced cancer stages (Arari et al, 1997). However, alterations in the HER-2/neu expression as a tumour progression marker from localised to metastatic PC have yet to be fully established. Nevertheless, in vitro and clinical studies have linked HER-2/neu expression to the development of late androgen-independent disease (Craft et al, 1999; Signoretti et al, 2000). These data suggest that HER-2 overexpression would be higher if a tumour sample can be obtained from patients with androgen-independent disease. This is a difficult challenge, because very few of these patients have diseases that can be biopsied readily, because metastatic PC involve mostly the skeleton.

To date, cancer-targeting therapy by trastuzumab is only indicated for metastatic breast cancer patients with an over-expression of HER-2/neu by IHC (3+), while in PC this has not yet been evaluated.

In the present study, we evaluated the frequency of the expression of HER-2/neu in CTCs of patients with localised PC vs patients with metastatic PC. HER-2/neu was detected in 54% of CTCs of patients with a metastatic disease and in 9.6% of CTCs of patients with localised PC (P = 0.004). This result suggests a potential value for HER-2/neu as a marker of tumour progression even when evaluated in CTCs. Indeed, the precise phenotypic profile of the CTCs truly responsible for clinical metastasis is not known to date. Table 4 summarises our results as compared to previously published manuscripts.

Among the 31 patients with localised PC, 16 patients were classified as 'low-risk patients' (serum PSA ≤ 10 and Gleason score ≤ 6) and 15 patients were classified as 'intermediate or high-risk patients' (PSA: 10–20 or Gleason score = 7 and PSA > 20 or Gleason score: 8–10). One of 16 patients and two of 15 patients are positive for the detection of HER-2/neu in these groups, retrospectively. To establish whether patients with localised disease and HER-2/neu-positive CTCs are at a higher risk of recurrence will

Table 4 RT-PCR or PCR detection of CTC and BM micrometastases in PC

| Author          | Marker     | Sample | Localised PC | Metastatic PC |
|-----------------|------------|--------|--------------|---------------|
| Kaz et al       | PSA mRNA   | Blood  | 25/65 (38%)  | 14/18 (78%)   |
| Israeli et al   | PSA mRNA   | Blood  | 0/18 (0%)    | 6/24 (25%)    |
| Seiden et al    | PSA mRNA   | Blood  | 0/18 (0%)    | 6/24 (25%)    |
| Ghosein et al   | PSA mRNA   | Blood  | 4/25 (16%)   | 26/76 (34%)   |
| Sokoloff et al  | PSA mRNA   | Blood  | 43/69 (62%)  | 29/33 (88%)   |
| Corey et al     | PSA mRNA   | Blood  | 12/69 (17%)  | 13/33 (39%)   |
| Wood and Banerjee | PSA mRNA | BM     | 45/63 (71%)  | 10/13 (77%)   |
| Megeran et al   | PSA mRNA   | Blood  | 4/25 (16%)   | 26/76 (34%)   |
| Laribi et al    | Prostasin mRNA | Blood | 18/69 (26%)  | 17/27 (63%)   |
| Hara et al      | PSA mRNA   | Blood  | 1/41 (2.4%)  | 7/14 (50%)    |
| PSA mRNA        | Blood      | NA     | 9/9 (100%)   |
| PSCA mRNA       | Blood      | 0/41 (0%) | 7/14 (50%)  |
| Present series  | HER-2/neu mRNA | Blood | 3/31 (9.6%)  | 6/11 (54%)    |

CTC = circulating tumour cell; BM = bone marrow; PC = prostate cancer; PSA = prostate specific antigen; PSMA = prostate specific membrane antigen; PSCA = prostate stem cell antigen.
require additional follow up. The status of HER-2/neu in the primary tumours of the patient population is unfortunately not available and will be very difficult to obtain since many patients were referred from outside centres.

In summary, the presence of HER-2/neu in CTCs of patients with PC is more frequent in patients with metastases than those with localised disease. This technique may be of great assistance to identify patients who may benefit from targeting HER-2/neu in the clinic. In the future, additional studies should evaluate a panel of different biomarkers in CTCs. This panel may include biomarkers (such as MMP2, MMP9 or E-cadherine) able to better predict the biological behaviour of CTCs (i.e. clinical metastasis). One limitation to this approach will be the amount of CTCs and therefore the corresponding RNA concentration available for such studies.

ACKNOWLEDGEMENTS

The work in the LS laboratory was supported by contract number FIGH-CT-1999-00002 from the CEC (Susgenimdrac).

REFERENCES

Agus DB, Scher HI, Higgins B, Fox WD, Heller G, Fazzari M, Cordon-Cardo C, Golde DW (1999) Response of prostate cancer to anti-HER-2/neu antibody in androgen-dependent and independent human xenograft models. Cancer Res 59: 4761 – 4764

Arai Y, Yoshiki T, Yoshida O (1997) c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. Prostate 30: 195 – 201

Corey E, Arfman EW, Owson MM, Melchior SW, Tindall DJ, Young C Y-F, Ellis WJ, Vessella RL (1997) Detection of circulating prostatic cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostatic-specific antigen (PSA) messages. Urology 50: 184 – 188

Craft N, Shostak Y, Carey M, Sawyers C (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signalling by the HER-2/neu tyrosine kinase. Nat Med 5(3): 280 – 285

De Marzo AM, Putzi MJ, Nelson WG (2001) New concepts in the pathiology of prostatic epithelial carcinogenesis. Urol 37(Suppl 4A): 103 – 114

Ecske SA (2001) The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammal Gland Biol Neoplas 6(4): 393 – 406

Fossa A, Lilleby W, Fossa SD, Gaudernack G, Torlakovic G, Berner A (2002) Independent prognostic significance of HER-2/neu oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy. Int J Cancer 99: 100 – 105

Ghossein RA, Scher HI, Gerald WL, Kelly WK, Curley T, Amsterdam A, Zhang Z-F, Rosai J (1995) Detection of circulating tumour cells in patients with localised and metastatic prostatic carcinoma: clinical implications. J Clin Oncol 13: 1195 – 1200

Gu K, Mes-Masson AM, Gauthier J, Saad F (1996) Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. Cancer Lett 99: 185 – 189

Hara N, Kasahara T, Kawasaki T, Bilim V, Obara K, Takahashi K, Tomita Y (2002) Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one millilitre of peripheral blood. Clin Cancer Res 8(6): 1794 – 1799

Hynes NE (1993) Amplification and overexpression of the erbB-2 gene in human tumours: its involvement in tumour development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol 4: 19 – 26

Hynes NE, Stern DF (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198: 165 – 184

Israel RS, Miller WH, Su SL, Powell CT, Fair WR, Samadi DS, Huryk RF, DeBlasio A, Edwards ET, Wise GJ, Heston WD (1994) Sensitive nested reverse transcription polymerase chain reaction of human glandular kallikrein (hK2) and prostatic-specific antigen (PSA) messages. Urology 50: 184 – 188

Katz AE, Olsson CA, Raffo AJ, Cama C, Perlman H, Seaman E, O’Toole KM, Hynes NE, Stern DF (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. Cancer Res 54: 6306 – 6310

Latza U, Niedobitek G, Schwarting R, Nekarda H, Steinh (1990) Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelia. J Clin Pathol 43: 213 – 219

Mejean A, Vona G, Nalpas B, Damotte D, Brousse N, Chretien Y, Dufour B, Lacour B, Bréchot C, Paterlini-Brèchot P (2000) Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence. J Urol 163: 2022 – 2029

Menard S, Tagliabue E, Camgipilo M, Pupa SM (2000) Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 182: 150 – 162

Morriss MJ, Reuter VE, Kelly WK, Stovin SF, Kenneson K, Verbel D, Osman I, Scher HI (2002) HER-2 profiling and targeting in prostate carcinoma. A phase II trial of trastuzumab alone and with paclitaxel. Cancer 94(4): 984 – 986

O-charoenrat P, Rhys-Evans PH, Modjahedi H, Eccles SA (2002) The role of c-erbB receptor and ligands in head and neck squamous cell carcinoma. Oral Oncology 38: 627 – 640

Osman I, Scher HI, Drobnjak M, Verbel D, Morris M, Agus D, Ross JS, Cordon-Cardo C (2001) HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 7: 2643 – 2647

Pergram MD, Finn RS, Arzoo K, Berrty M, Pietras RJ, Slamon DJ (1997) The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15: 537 – 547

Ross JS, Sheehan CE, Hayner-Buchan AM, Ambros RA, Kallakury BVS, Kaufman RP, Fisher HAG, Rifkin MD, Murapa P (1997) Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization in vivo of prostate cancer. Cancer 79(11): 2162 – 2170

Sadsasivan R, Morgan R, Jennings S, Austenfeld M, Van Velthuizen P, Stephens R, Noble M (1993) Overexpression of HER-2/neu may be an indicator of poor prognosis in prostate cancer. J Urol 150: 126 – 131

Schechter AL, Hung MC, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U, Ullrich A, Coussens L (1985) The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 229: 976 – 978

Scher HI, Heller G (2000) Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 55: 323 – 327

Seiden MV, Kantoff PW, Krihtav K, Bryant M, Haltom E, Gaynes L, Kaplan I, Bubley G, DeWolf W, Sklar J (1995) Detection of circulating tumour cells in men with localized prostate cancer. J Clin Oncol 13: 2634 – 2639

Signoretti S, Montironi R, Manola J, Altman A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M (2000) Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 92(23): 1918 – 1925

Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Basela J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpressed HER2. N Engl J Med 344: 783 – 792

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 235: 177 – 182

Small EJ, Bok R, Reese DM, Sudilovsky D, Frohlich M (2001) Docetaxel, estramustine, plus platsutuzumab in patients with metastatic androgen-independent prostate cancer. Sem Oncol 4(15): 71 – 76

Sokoloff MH, Tso CL, Kaboo R, Nelson S, Ko J, Dorey F, Figlin RA, Pang S, DeKernion J, Beldegrand A (1996) Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging:

© 2004 Cancer Research UK

British Journal of Cancer (2004) 90(2), 443 – 448
a clinicopathological molecular analysis of 121 patients. *J Urol* 156: 1560–1566
Soria JC, Gauthier LR, Raymond E, Granotier C, Morat L, Armand J-P, Boussin FD, Sabatier L (1999) Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients. *Clin Cancer Res* 5: 971–975
Wood DP, Banerjee M (1997) Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease free survival. *J Clin Oncol* 15: 3451–3457
Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K (1996) Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. *Nature* 319: 230–234
Yamauchi H, Stearns V, Hayes DF (2001) When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. *J Clin Oncol* 19: 2334–2356
Zhau HYE, Zhou J, Fraser Symmans WF, Chen B-Q, Chang S-M, Sikes RA, Chung LWK (1999) Transfected neu oncogene induces human prostate cancer metastasis. *Prostate* 28: 73–83